LataMed AI Corp. (OTC: LMED), a healthcare technology company specializing in digital health and artificial intelligence solutions for Latin America, announced today that its Venezuelan subsidiary, LATAMEDAI VE, has entered into an agreement with DROGUERIAS LALA C.A. to develop artificial intelligence-supported and automated software tools for pharmaceutical and laboratory operations. The collaboration aims to design, develop, test, and evaluate customized technology to support workflows in pharmaceutical research, laboratory testing, quality control, documentation, operational coordination, and data analysis.
The proposed technology is expected to include software tools that organize and analyze information generated during pharmaceutical development and laboratory activities. Planned functionality may encompass workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools intended to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage. LataMed AI and DROGUERIAS LALA will begin by identifying specific workflows to address, defining technical and operational requirements, and establishing a phased development and testing process. They will also set up confidentiality, information-security, data-management, and access-control procedures.
The parties will evaluate whether the technology can assist qualified personnel in organizing and reviewing information related to pharmaceutical formulas, laboratory results, quality standards, testing procedures, and approval processes. Any such functionality would serve as a decision-support and workflow-management resource and would not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions. All pharmaceutical, scientific, laboratory, and quality-control determinations would remain the responsibility of appropriately qualified professionals and regulatory authorities, with the technology not replacing independent professional judgment.
Dr. Kevin Rodan Levy, CEO of LataMed AI, commented, "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
Management believes this collaboration could expand LataMed AI's technology into enterprise pharmaceutical and laboratory applications beyond its patient-facing telemedicine services. The initiative aligns with the company's broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, and other ecosystem participants. If successfully developed, the technology might provide a framework adaptable for other organizations in Venezuela and Latin America, subject to separate agreements, successful testing, operational readiness, and regulatory requirements.
The agreement establishes a framework for development and evaluation but does not guarantee a specific implementation schedule, commercial deployment, cost reductions, scientific or regulatory outcomes, revenue, or expansion. The company will provide updates as development progresses. For more information, visit https://latamed.ai or review SEC filings at www.sec.gov.
